AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24708509 — intervention group
Group type: EXPERIMENTAL
Intervention: Botsourcing jobs requiring cognition
Number of subjects: 0
Study 24708509 — intervention group
Group type: EXPERIMENTAL
Intervention: Botsourcing jobs requiring emotion
Number of subjects: 0
Study 24708509 — intervention group
Group type: EXPERIMENTAL
Intervention: Botsourcing jobs requiring emotion with robots conveying more emotion
Number of subjects: 0
Study 24708509 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsourcing cognition-oriented jobs
Number of subjects: 0
Study 24708509 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsourcing emotion-oriented jobs
Number of subjects: 0
Study 22613585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked polyelectrolyte (CLP)
Number of subjects: 111
Study 20431290 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 227
Study 20431290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 18327970 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand local anesthetic system at a deposition rate of 45 seconds (fast injection)
Number of subjects: 61
Study 18327970 — intervention group
Group type: COMPARATOR
Intervention: Wand local anesthetic system at a deposition rate of 4 minutes and 45 seconds (slow injection)
Number of subjects: 61
Study 18327970 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe injection at a deposition rate of 4 minutes and 45 seconds (slow injection)
Number of subjects: 61
Study 15912483 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (average 40 mg and 28 mg alcohol/100 ml blood at the beginning and end of drive)
Number of subjects: 8
Study 15912483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 8
Study 15912483 — intervention group
Group type: COMPARATOR
Intervention: Control drink (double blind)
Number of subjects: 8
Study 12897272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt tympanostomy tube insertion
Number of subjects: 429
Study 12897272 — intervention group
Group type: COMPARATOR
Intervention: Late tympanostomy tube insertion
Number of subjects: 429
Study 12897272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative durations of MEE
Number of subjects: 429
Study 10391361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycor (3 microg/kg/min)
Number of subjects: 139
Study 8929262 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 200
Study 8929262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel therapeutic course
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial full dose of praziquantel followed by suppressive doses
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial loading praziquantel dose followed by suppressive dose at monthly intervals
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metrifonate therapeutic course followed by prophylactic course monthly
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of oral praziquantel
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate orally every month
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose of praziquantel orally every month
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metrifonate curative course every 2 weeks for 3 doses every 6 months
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral monthly praziquantel prophylactic dose
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel prophylactic doses at 3-monthly intervals
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo in the form of vitamin B complex tablets at 3-monthly intervals
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral monthly therapeutic dose of metrifonate
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral monthly prophylactic doses of praziquantel
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo in the form of 2 vitamin B-complex tablets monthly
Number of subjects: 14
Study 1908498 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 14
Study 6684447 — intervention group
Group type: EXPERIMENTAL
Intervention: febuprol (Valbil)
Number of subjects: 712
Study 30413359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based interactive distraction (TBID; 1 minute preseparation)
Number of subjects: 102
Study 30413359 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (15 to 45 minutes of preseparation)
Number of subjects: 102
Study 28738939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins (CSMs)
Number of subjects: 235
Study 28738939 — intervention group
Group type: COMPARATOR
Intervention: No cavity shave margins (CSMs)
Number of subjects: 235
Study 25853795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket (3M SmartClip)
Number of subjects: 138
Study 25853795 — intervention group
Group type: COMPARATOR
Intervention: Conventional bracket (3M Victory)
Number of subjects: 138
Study 24647921 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (titrated to 2 mg)
Number of subjects: 35
Study 24647921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22922245 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Coach intervention (IVR-enhanced care transition intervention)
Number of subjects: 0
Study 22922245 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 18716800 — intervention group
Group type: EXPERIMENTAL
Intervention: full-mouth disinfection plus essential oils (Listerine)
Number of subjects: 20
Study 18716800 — intervention group
Group type: COMPARATOR
Intervention: full-mouth disinfection plus placebo
Number of subjects: 20
Study 17698729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol dietary counseling
Number of subjects: 1062
Study 17698729 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (Control)
Number of subjects: 1062
Study 16307708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 461
Study 16307708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 461
Study 16307708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 461
Study 16307708 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 461
Study 16307708 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 461
Study 16307708 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 461
Study 12049862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolisation (gelatin sponge plus doxorubicin)
Number of subjects: 112
Study 12049862 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolisation (gelatin sponge)
Number of subjects: 112
Study 12049862 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control)
Number of subjects: 112
Study 12049862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolisation
Number of subjects: 112
Study 9535410 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dermal glucocorticoid sensitivity
Number of subjects: 137
Study 9535410 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced glucocorticoid sensitivity and secretion of cortisol
Number of subjects: 137
Study 9535410 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tissue sensitivity to cortisol
Number of subjects: 137
Study 8562040 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg EMD 55900
Number of subjects: 12
Study 8562040 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg EMD 55900
Number of subjects: 12
Study 8562040 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EMD 55900
Number of subjects: 12
Study 2708742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (daily oral dose, 30 mg, and intravenous dose during dialyses, 5 mg)
Number of subjects: 15
Study 2708742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2708742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (daily dose of 30 mg for 6 months after trial)
Number of subjects: 15
Study 778987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (400 mg/day)
Number of subjects: 40
Study 778987 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg/day)
Number of subjects: 40
Study 30377243 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric heating
Number of subjects: 34
Study 30377243 — intervention group
Group type: COMPARATOR
Intervention: Control (quick‐light charcoal)
Number of subjects: 34
Study 31196131 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure group (arterial pressure > 60 mmHg)
Number of subjects: 90
Study 31196131 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean arterial pressure 47 ± 5 mmHg)
Number of subjects: 90
Study 31196131 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure group
Number of subjects: 90
Study 31196131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 27807279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES)
Number of subjects: 126
Study 27807279 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 126
Study 27807279 — intervention group
Group type: EXPERIMENTAL
Intervention: PES
Number of subjects: 126
Study 25073872 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 46
Study 25073872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23124529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group therapy (n = 33)
Number of subjects: 65
Study 23124529 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (n = 32)
Number of subjects: 65
Study 23124529 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (control group)
Number of subjects: 65
Study 21750426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg, orally)
Number of subjects: 0
Study 21750426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19841125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 100
Study 19841125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19841125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy (initiated between 7 and 14 days of life)
Number of subjects: 100
Study 19841125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initiated between 7 and 14 days of life)
Number of subjects: 100
Study 16751063 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 16751063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study 15286528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (CRP)
Number of subjects: 65
Study 15286528 — intervention group
Group type: COMPARATOR
Intervention: No participation in CRP (Control)
Number of subjects: 65
Study 11350509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine gel (Oraqix) applied for 30 seconds
Number of subjects: 30
Study 11350509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine gel (Oraqix) applied for 2 minutes
Number of subjects: 30
Study 11350509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine gel (Oraqix) applied for 5 minutes
Number of subjects: 30
Study 10036600 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms)
Number of subjects: 1016
Study 10036600 — intervention group
Group type: COMPARATOR
Intervention: Gestodene (75 micrograms)
Number of subjects: 1016
Study 10036600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1016
Study 8182837 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of one-half to one clove of garlic per day
Number of subjects: 0
Study 2558186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6) 50 mg per day
Number of subjects: 63
Study 2558186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 765457 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate (Monistat Cream 2%) administered once daily at bedtime for 14 days
Number of subjects: 95
Study 765457 — intervention group
Group type: COMPARATOR
Intervention: Nystatin vaginal tablets (100,000 units each) administered twice daily for 15 days
Number of subjects: 95
Study 29497091 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and fulvestrant
Number of subjects: 0
Study 28126581 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS (Collaborative Assessment and Management of Suicidality) therapy
Number of subjects: 104
Study 28126581 — intervention group
Group type: COMPARATOR
Intervention: Usual intensive inpatient treatment (Control)
Number of subjects: 104
Study 28126581 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS and Control (combined)
Number of subjects: 104
Study 26025994 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg three times daily
Number of subjects: 112
Study 26025994 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 2.5 mg four times daily
Number of subjects: 112
Study 22978252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of beclomethasone (BDP) 50μg and formoterol 6μg (Foster® pMDI)
Number of subjects: 20
Study 22978252 — intervention group
Group type: COMPARATOR
Intervention: Free combination of BDP 200μg and formoterol 24μg
Number of subjects: 20
Study 20855350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 22
Study 20855350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 40 mg
Number of subjects: 22
Study 20855350 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 50 mg
Number of subjects: 22
Study 20855350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with thalidomide (TAD)
Number of subjects: 138
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with adriamycin and dexamethasone in combination with vincristin (VAD)
Number of subjects: 138
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with bortezomib (PAD)
Number of subjects: 138
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ASCT (after high-dose melphalan and autologous stem cell transplant)
Number of subjects: 138
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment levels of VWF, fibrinogen and FVIII:C
Number of subjects: 138
Study 18241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factor abnormalities before and during treatment
Number of subjects: 138
Study 16817845 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 224
Study 16817845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 14986871 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDA standard HIV intervention
Number of subjects: 200
Study 14986871 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural-focused HIV intervention
Number of subjects: 200
Study 10560987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis for aneuploidy
Number of subjects: 262
Study 10560987 — intervention group
Group type: COMPARATOR
Intervention: Assisted zona hatching (Control)
Number of subjects: 262
Study 8880364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-tone paradigm (target tone only, standard replaced by silence)
Number of subjects: 0
Study 8880364 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-tone paradigm (target and standard tones presented every 2.0 s, target-tone probability 0.10)
Number of subjects: 0
Study 8880364 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-tone paradigm (target tone probability 0.10, standard tone probability 0.80, nontarget tone probability 0.10)
Number of subjects: 0
Study 2127269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 236
Study 7361272 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% amino acids (essential and nonessential)
Number of subjects: 12
Study 7361272 — intervention group
Group type: COMPARATOR
Intervention: 3.5% amino acids with 2.5% glucose
Number of subjects: 12
Study 31725311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer ($300/year)
Number of subjects: 10000
Study 31725311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized community-supported agriculture (CSA) ($300/year subsidy)
Number of subjects: 10000
Study 31437124 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (inhalation of essential oil blend)
Number of subjects: 0
Study 31437124 — intervention group
Group type: COMPARATOR
Intervention: Control (odorless vegetable oil blend)
Number of subjects: 0
Study 28327083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive-aerobic bicycle training (interactive cycling)
Number of subjects: 0
Study 28327083 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aerobic bicycle training
Number of subjects: 0
Study 28327083 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (stretching and toning exercises)
Number of subjects: 0
Study 25599314 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-directed education (pamphlet and video about vaccination pain management)
Number of subjects: 160
Study 24512193 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 24512193 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study 21596485 — intervention group
Group type: COMPARATOR
Intervention: 5 Gy within 7 fractions (Group 1)
Number of subjects: 200
Study 21596485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Gy within 10 fractions (Group 2)
Number of subjects: 200
Study 21045083 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally daily until disease progression
Number of subjects: 40
Study 21045083 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg orally daily
Number of subjects: 40
Study 17351253 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-gemcitabine (standard arm)
Number of subjects: 250
Study 17351253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone (experimental arm)
Number of subjects: 250
Study 15661436 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal procedural pain exposure (number of skin breaking procedures)
Number of subjects: 87
Study 15661436 — intervention group
Group type: COMPARATOR
Intervention: Morphine exposure since birth
Number of subjects: 87
Study 11873239 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous IL-2 therapy
Number of subjects: 28
Study 11873239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous IL-2 therapy
Number of subjects: 28
Study 11873239 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-2 therapy
Number of subjects: 28
Study 11873239 — intervention group
Group type: EXPERIMENTAL
Intervention: All IL-2 therapies
Number of subjects: 28
Study 10444908 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medical services included in the basic cover for 3 years (experimental group)
Number of subjects: 7500
Study 10444908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to complementary medical services)
Number of subjects: 7500
Study 7789452 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing perceived curvature of normally straight sagittal movements
Number of subjects: 0
Study 7789452 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing curvature of normally curved transverse movements
Number of subjects: 0
Study 7789452 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing curvature of naturally curved transverse movements
Number of subjects: 0
Study 3292344 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 23
Study 3292344 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 23
Study 30586726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 12000
Study 30586726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 29723455 — intervention group
Group type: EXPERIMENTAL
Intervention: TESE (n = 50)
Number of subjects: 210
Study 29723455 — intervention group
Group type: EXPERIMENTAL
Intervention: TESA (n = 56)
Number of subjects: 210
Study 29723455 — intervention group
Group type: EXPERIMENTAL
Intervention: TEFNA (n = 64)
Number of subjects: 210
Study 29723455 — intervention group
Group type: EXPERIMENTAL
Intervention: micro-TESE (n = 40)
Number of subjects: 210
Study 25654585 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure guidance with albumin (ALB)
Number of subjects: 30
Study 25654585 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid protocols without COP support (control)
Number of subjects: 30
Study 22877571 — intervention group
Group type: EXPERIMENTAL
Intervention: Supermarket vouchers for 4 weeks
Number of subjects: 214
Study 22877571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 214
Study 21943782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra combined with MTX
Number of subjects: 50
Study 21943782 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 50
Study 18436293 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus casei CRL431 and Bifidobacterium lactis Bb‐12)
Number of subjects: 119